BioResponse


Manufacturer and originator of a microencapsulated diindolylmethane (DIM) ingredient and supplements. The company develops and licenses a microencapsulation delivery technology for oral DIM, supports clinical research on estrogen metabolism, holds related patents, supplies ingredient powder to manufacturers, and sells finished dietary supplement products direct-to-consumer and through wholesale channels.

Industries

Dietary Supplements
E-Commerce
Retail
Wellness and Fitness Services

Nr. of Employees

small (1-50)


Patents

Self-emulsifying formulations of DIM-related indoles

US-11337961-B2

View Details

Self-emulsifying formulations of DIM-related indoles

US-10799479-B2

View Details

Self-emulsifying formulations of DIM-related indoles

US-10441569-B2

View Details

Self-emulsifying formulations of DIM-related indoles

US-9918965-B2

View Details

Products

BioResponse DIM 150

Dietary supplement capsule containing 150 mg of microencapsulated diindolylmethane (DIM) per capsule; 60 capsules per bottle.

BioResponse DIM 75

Dietary supplement capsule containing 75 mg of microencapsulated diindolylmethane (DIM) per capsule.

DIM Palmetto

Finished dietary supplement product combining DIM with other ingredients, supplied as softgels.

DIM Enhanced

Finished dietary supplement product formulated with microencapsulated DIM, provided as vegetarian capsules.


Services

Supply of microencapsulated active-ingredient powder and licensing of formulation technology to manufacturers and brands worldwide.

Wholesale pricing and private-label product options for health practitioners, pharmacies, and retailers via a wholesale group membership.

Expertise Areas

  • Formulation development for enhanced oral bioavailability
  • Microencapsulation delivery systems
  • Clinical pharmacokinetics and bioavailability assessment
  • Clinical trial collaboration and biomarker studies
  • Show More (3)

Key Technologies

  • Microencapsulation delivery systems
  • Extended-release oral formulation
  • Pharmacokinetic/bioavailability assays (blood sampling)
  • Accelerated and real-time stability testing
  • Show More (2)

News & Updates

Conference presentation on hormonal balance and DIM by company leadership.

Presentation on microencapsulated diindolylmethane formulation performance at a Controlled Release Society meeting.

Reference to a review and published abstract noting that indole-3-carbinol converts to DIM in vivo and that DIM is the active compound.

More than 15 published clinical studies have used the company's microencapsulated DIM formulation demonstrating bioavailability, safety, and tolerability.

Holder of numerous U.S. and international patents covering formulation technology and methods of use for diindolylmethane.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.